Clinical Trials Logo

Filter by:
NCT ID: NCT02367456 Completed - Clinical trials for Acute Myeloid Leukemia

A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients

BRIGHT 1012
Start date: April 28, 2015
Phase: Phase 1
Study type: Interventional

This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.

NCT ID: NCT02366897 Completed - Clinical trials for Drug-induced Extrapyramidal Side Effects

Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics

Start date: February 21, 2017
Phase: N/A
Study type: Interventional

The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are inadequately sensitive to refine practice. With all current and "pipeline" antipsychotics based on central dopamine blockade, there is little prospect that therapeutics can be improved by advances in pharmacology alone. The project uses, for the first time, technology that is not only simple, real-life and user-friendly but "modern" and socially held in high regards. The proposal depends on patients receiving antipsychotic medication where clinically indicated. At all times, subjects will receive clinically-indicated therapy. The major ethical issue will relate to the issue of informed consent in those suffering from major psychiatric disorder. This is a routine consideration in psychiatric practice and the investigators will seek guidance on this from the Consultant Psychiatrist responsible for potential participants and would not proceed with initial approaches in cases of doubt or absence of capacity. This is a pilot/feasibility study with no intention to utilise the data for commercialisation of the device or to expand the CE (Conformité Européenne) marking.

NCT ID: NCT02366195 Completed - Clinical trials for Unresected Stage IIIb to IVM1c Melanoma

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

TVEC-325
Start date: April 7, 2015
Phase: Phase 2
Study type: Interventional

The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the safety and tolerability profile of talimogene laherparepvec.

NCT ID: NCT02365987 Completed - Healthy Men Clinical Trials

The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety

INTERFAT
Start date: February 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether there are differences in postprandial metabolic indices following interesterified fats used in commercial spreads versus the corresponding un-interesterified blend.

NCT ID: NCT02365610 Completed - Epilepsy Clinical Trials

A Study of GWP42006 in People With Focal Seizures - Part B

Start date: March 2016
Phase: Phase 2
Study type: Interventional

To investigate the potential antiepileptic effects of GWP42006 as add-on therapy in subjects with inadequately controlled focal seizures.

NCT ID: NCT02365103 Completed - Clinical trials for Anemia, Iron-Deficiency

Tea Consumption and Iron Bioavailability in Women Using a Stable Isotope

Start date: November 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the inhibition effect of tea consumption on non haem iron absorption with the use of an iron tracer. The study also aims to assess the effect of time variability of tea consumption on non haem iron absorption from a typical western breakfast.

NCT ID: NCT02364635 Completed - Healthy Clinical Trials

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Start date: February 2015
Phase: Phase 1
Study type: Interventional

PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects Objective: - To assess the safety and tolerability of single ascending oral doses of icosabutate in healthy subjects - To evaluate the pharmacokinetic (PK) parameters of icosabutate in healthy subjects

NCT ID: NCT02364427 Completed - Acute Kidney Injury Clinical Trials

Arterial Stiffness and AKI Post-CABG

Heart-AKI
Start date: April 2015
Phase:
Study type: Observational

Acute Kidney Injury is a condition where your kidneys suddenly stop working properly and usually occurs if you are already unwell with an illness and can happen after having surgery. Having an episode of acute kidney injury increases the risk of progression to chronic kidney disease (CKD) later on and decreases long-term survival. It also has a major socioeconomic impact with regards to admissions and length of hospital stay. There is currently no universally accepted treatment or method of identifying patients that are at risk. The investigators aim to measure arterial stiffness in patients prior to them undergoing cardiac surgery to investigate whether this measurement is associated with an increased risk of patients developing acute kidney injury after surgery. The investigators are planning to measure arterial stiffness, and examine a blood sample, for kidney health-related levels to determine whether there is an association between those patients who have stiff arterial vessels and those patients who may develop acute kidney injury after surgery.

NCT ID: NCT02364414 Completed - Orthodontics Clinical Trials

The Accuracy of Direct Digital Intra-oral Scanning Measurements Compared to Measurements on Study Models

Start date: December 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the accuracy of measurements derived from a commercially available direct intra-oral scanning system with those taken from plaster study models, and to compare cost implications of both systems. The investigators will test the hypotheses: - There is no systematic difference between measurements taken from the Trios scanner and study models. - There is no difference in the cost of producing digital models.

NCT ID: NCT02363088 Completed - Cervical Carcinoma Clinical Trials

Can Text Reminders Improve Uptake of Cervical Screening?

Start date: February 2015
Phase: N/A
Study type: Interventional

Cervical cancer is the most common cancer in women under 35 years and is a major public health concern. Fortunately, the natural history of this malignancy can be beneficially improved through cytological screening. However, the success of screening programmes depends on their ability to attract the "at risk" population, as well as the analytical sensitivity and specificity of the screening test. In the UK, screening consistently falls short of the 80% national target and recent evidence shows uptake is decreasing, in part due to the introduction of HPV vaccination programmes. In the under 30s London population, average coverage only reached 50% in 2013. Given this information, the cervical screening programme is under increasing pressure to improve uptake, and need an evidence based intervention. We aim to improve the uptake of cervical screening using SMS messaging through a randomised controlled trial. The trail will evaluate both the prevalent and incident rounds of screening and within the intervention group, analyse how the content of text reminders influences their effectiveness. Specifically we will evaluate a) neutral b) messenger c) social norms d) framed gain/loss reminders. Unlike our previous trial, this SMS reminder will encourage the booking of an appointment which has never been tested, rather than simply reminding women to attend. All women being invited for cervical screening, registered at participating GPs within Hillingdon will be eligible to participate. Women will also be provided with a 2 week window during which they can opt out of the research. Given the sample sizes we predict the trial will take 9 months.